Godavari Drugs Limited (530317) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Godavari Drugs Limited ₹76.39, price ₹118, upside -35.3%, quality 11 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Godavari Drugs Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 25, 2026.
How to read this chart
60‑month range ₹52.20 – ₹147.75 · fair‑value band ₹53.47 – ₹99.31 · the ₹118.05 price screens above the ₹76.39 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 25, 2026.
Follow Godavari Drugs in your weekly email
Every Wednesday you see whether Godavari Drugs is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Godavari Drugs Limited manufactures and supplies active pharmaceutical ingredients (APIs), drug intermediaries, and fine chemicals in India.
Show more
Godavari Drugs Limited manufactures and supplies active pharmaceutical ingredients (APIs), drug intermediaries, and fine chemicals in India. It offers APIs, including ciprofloxacin HCl, ciprofloxacin lactate, ciprofloxacin betaine, mefenamic acid, enrofloxacin, and elthambutoal HCI; and intermediaries, such as A D lactone for spironolactone and 6 mercaptopurine for azathioprine. The company also provides loan license and contract manufacturing services. It serves the life science industry. The company was incorporated in 1987 and is based in Secunderabad, India.
Stock analysis
Godavari Drugs Limited (530317) currently trades at ₹118.05, while our model-based Fair Value estimate is ₹76.39, 35.3% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹106.25 per share, and 3 of the 13 models we run sit above the ₹118.05 price.
Bear case: the Asset-Based group reads lowest at ₹67.44, and 10 of the 13 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹53.47 (bear) to ₹99.31 (bull), the price of ₹118.05 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 11/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Godavari Drugs Limited reported revenue of ₹1.1B in FY2026 versus ₹1.6B in FY2022, a compound −10.0%/yr. Reported net income was ₹40.9M in FY2026, compounding −6.0%/yr from FY2022.
Key figures
Market cap ₹270M (≈ $2.8M) · P/E ratio 11.0 · P/S ratio 0.42 · EPS (TTM) ₹3.22 · Net margin 3.9% · Return on assets (EBIT) 7.0% · Operating margin 5.8% · Revenue (TTM) ₹993M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 9% below its 52-week high and 68% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −35%, 530317 screens richer than that median.
Fair Value models
Bear ₹53.47Fair Value ₹76.39Bull ₹99.31
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹1.64 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.8/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−6.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.9%
Start year 2021 (pandemic). Over 10 years: +2.9% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.3%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−5.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−5.9%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−5.9% vs 6.8%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 7%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks
Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score11 · Bottom 25%
Fair Value upside−54.1% · Below median
Profitability
Return on assets0.0% · Below median
Net margin (TTM)2.4% · Below median
Operating margin (TTM)5.8% · Below median
Growth and dividend
Revenue growth15.0% · Above median
Dividend yield (TTM)0.0% · Bottom 25%
Balance sheet
Debt / equity0.49× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)11.0× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 17
FUTURE (revenue growth)75· sector 24
PAST (return on equity)0· sector 27
HEALTH (low debt)76· sector 96
DIVIDEND (yield)0· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Godavari Drugs Limited (530317) overvalued or undervalued?
As of Sep 25, 2026, our model estimates a fair value of ₹76.39 versus a price of ₹118.05, about −35% upside (overvalued).
What is the fair value of 530317?
Our model-based fair value for Godavari Drugs Limited is ₹76.39 (as of Sep 25, 2026), built from audited fundamentals. The current price: ₹118.05.
What is the quality score of 530317?
Godavari Drugs Limited has a Quality Score of 11/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Godavari Drugs Limited (530317)?
Our model-based price target is the fair value of ₹76.39 (as of Sep 25, 2026) from 13 valuation models. Cautious scenario ₹53.47, optimistic scenario ₹99.31. It is a calculation from audited fundamentals, not an analyst target.
What is the Godavari Drugs Limited stock forecast for 2026?
Our models put fair value at ₹76.39, about −35% upside versus a price of ₹118.05 (overvalued). Cautious scenario ₹53.47, optimistic scenario ₹99.31. The calculation is refreshed regularly with new filings.
What is the revenue of Godavari Drugs Limited (530317)?
Godavari Drugs Limited reported trailing-twelve-month revenue of about ₹993M (latest available figure, as of Sep 25, 2026).
What is the intrinsic value of Godavari Drugs Limited (530317)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Godavari Drugs Limited it is ₹76.39 per share (as of Sep 25, 2026), against a price of ₹118.05. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is Godavari Drugs Limited stock overvalued or undervalued in 2026?
As of Sep 25, 2026, 530317 trades above its calculated fair value: price ₹118.05, fair value ₹76.39, a gap of about −35% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 530317?
No. The price is what the market pays today (₹118.05); the fair value is what the company's own numbers justify (₹76.39). For Godavari Drugs Limited the two are ₹41.66 per share apart. That gap is exactly why we show both numbers side by side.
How much is Godavari Drugs Limited worth?
The market values Godavari Drugs Limited at about ₹270M (market capitalisation, as of Sep 25, 2026). Per share that is ₹118.05; our models calculate a fair value of ₹76.39 per share.
What do the bullish and bearish scenarios say about 530317?
Our models span a range for Godavari Drugs Limited: cautious scenario ₹53.47, base ₹76.39, optimistic ₹99.31 per share (as of Sep 25, 2026, price ₹118.05). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 530317?
Godavari Drugs Limited trades at a price-to-earnings ratio of 11.0 (as of Sep 25, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹76.39 is built from several models across several years.
How solid is the balance sheet of Godavari Drugs Limited (530317)?
Balance-sheet figures for Godavari Drugs Limited (as of Sep 25, 2026): debt of 0.49 per unit of equity. They feed the Quality Score of 11/100, which measures business quality independently of the share price.
How far is 530317 from its 52-week high?
Godavari Drugs Limited trades at ₹118.05, about 9% below its 52-week high of ₹130.15 and 68% above the low of ₹70.24 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹76.39 is for.
Which stocks are comparable to Godavari Drugs Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Godavari Drugs Limited stock attractive at the current price?
The data as of Sep 25, 2026: price ₹118.05, calculated fair value ₹76.39 (−35%), Quality Score 11/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 530317 calculated?
We run Godavari Drugs Limited through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹76.39, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Godavari Drugs Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Godavari Drugs Limited (530317)?
The closing price on Oct 1, 2026 was ₹118.05. Our model-based fair value is ₹76.39, about −35% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Godavari Drugs Limited right now?
The price sits above even our optimistic bull case (₹99.31). The favourable scenario is already priced in. Weak quality (11/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (₹53.47 to ₹99.31) leaves room in how you read the outcome.
Key figures of Godavari Drugs Limited
How large is the market capitalisation of Godavari Drugs Limited (530317)?
The market capitalisation of Godavari Drugs Limited is ₹270M (≈ $2.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Godavari Drugs Limited (530317)?
The price-to-sales ratio of Godavari Drugs Limited is 0.42 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Godavari Drugs Limited (530317)?
Earnings per share at Godavari Drugs Limited are ₹3.22 (price ÷ EPS = P/E 11.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Godavari Drugs Limited (530317)?
The net margin of Godavari Drugs Limited is 3.9% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Godavari Drugs Limited (530317)?
On an EBIT basis the return on assets of Godavari Drugs Limited is 7.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Godavari Drugs Limited (530317)?
The operating margin of Godavari Drugs Limited is 5.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Godavari Drugs Limited (530317)?
Revenue at Godavari Drugs Limited is growing +15.0% versus a year earlier (3y avg −12.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Godavari Drugs Limited (530317)?
Earnings per share at Godavari Drugs Limited are growing +98.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Godavari Drugs Limited (530317) generate?
The free cash flow of Godavari Drugs Limited is −₹260M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Godavari Drugs Limited (530317) carry?
The net debt of Godavari Drugs Limited is ₹618M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Godavari Drugs Limited in the live analysis
One click puts Godavari Drugs Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
